Somatic CRISPR editing of Msh3 mitigates Huntington's disease pathology in mice.

Somatic CRISPR editing of *MSH3* to slow somatic CAG repeat expansion in *HTT*

This bioRxiv preprint demonstrates that somatic CRISPR editing of MSH3 mitigates Huntington's disease pathology in mice. MSH3, a mismatch repair protein, drives progressive somatic CAG repeat expansion in HTT — a key mechanism of symptom worsening. Its deletion in striatal neurons reduces somatic expansion and improves neuropathological outcomes.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Targeting MSH3 rather than HTT directly is an elegant strategy: reducing the somatic expansion that worsens disease without modifying the germline mutation. The mouse results are compelling, but clinical translation (AAV delivery, timing, target cells) remains the real challenge.

Clinical impact: 3/3 · Evidence strength: 3/3 · Novelty: 2/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 9/10